Document is current
Any future updates will be listed below
-
Authors
Hernes, S. S.
Nordnes, P. R.
Hol, H. R.
Ringstad, G.
Knapskog, A. B.
Emhjellen, P.
Løhaugen, G.
Emini, M.
Edwin, T. H.
-
Funding
Funding for this research was provided by:
KLINBEFORSK (2019208)
Helse Sør-Øst RHF (2023085)
Sørlandet Sykehus HF
- License Information
-
More Information
Article History
Received: 30 January 2025
Accepted: 3 April 2026
First Online: 7 May 2026
Declarations
:
: Ethical approval was assigned by the Norwegian regional committee for medical and health research ethics (REK) 77084. All participants will provide written informed consent.
: Not applicable since there are no individual personal data in this manuscript. Informed consent materials are available from the corresponding author.
: The authors declare that they have no competing interests. Trine Holt Edwin has served as a rater in the Roche BN29553 and Boehringer-Ingelheim 1346.0023 studies. Additionally, she is currently a subinvestigator in the GSK 219867 PROGRESS_AD study, unrelated to the work submitted here. ABK has contributed to clinical trials for Roche (BN29553), Boehringer-Ingelheim (1346.0023), Novo Nordisk (NN6535-4730) and GSK (219867).
